Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Celyad Oncology Appoints Matt Kane as Chief Executive Officer

NextEdge Admin

17 Sep 2024

2 min 23 sec

Celyad Oncology has appointed Matt Kane as its new Chief Executive Officer, effective October 1st, 2024. Kane brings over 20 years of experience in leadership roles within biotechnology, including a pioneering background in genome editing and CAR T-cell therapies. He has led the development of the first gene insertion therapeutic cleared for clinical evaluation and directed the clinical testing of several allogeneic CAR T-cell therapies. Throughout his career, Kane has demonstrated both scientific and business acumen, successfully raising over $500M in equity financings and forming partnerships valued at over $4B.

Kane most recently served as CEO of Tune Therapeutics, where he spearheaded the development of a lead epigenetic editing therapeutic candidate. He previously co-founded Precision BioSciences in 2006 and served as its CEO until 2021, where he oversaw the company’s IPO and directed four allogeneic CAR T therapies into human clinical studies.

Hilde Windels, Chair of the Board at Celyad, expressed confidence in Kane’s ability to help the company achieve its ambitious goals, citing his expertise in the CAR T space and strong background in research, development, and intellectual property monetization. Kane expressed enthusiasm for joining Celyad and advancing its innovative CAR T-cell therapy pipeline.

Celyad Oncology is a biotechnology company focused on developing next-generation CAR T-cell therapies, utilizing proprietary technology platforms and intellectual property. Its mission is to harness these technologies to create transformative cancer treatments that have the potential to revolutionize the CAR T-cell therapy landscape.